DiaSorin

DiaSorin, headquartered in Saluggia, Italy, is a globally recognized leader in the laboratory diagnostics market, specializing deeply in the highly complex fields of immunodiagnostics and molecular diagnostics. For over 50 years, the company has been developing, producing, and commercializing sophisticated diagnostic reagent kits used globally in hospital and reference laboratories.

The company is particularly renowned for its flagship LIAISON® platform, a series of fully automated chemiluminescence analyzers that process specialized immunoassays with exceptional accuracy and speed. DiaSorin actively avoids highly commoditized, routine testing markets; instead, it dominates niche, high-value diagnostic segments. They offer an exceptionally comprehensive global menu of tests for infectious diseases, bone and mineral metabolism (including gold-standard Vitamin D testing), endocrinology, and gastrointestinal infections.

In recent years, DiaSorin has aggressively expanded its footprint in molecular diagnostics through strategic mega-acquisitions, most notably its acquisition of the US-based Luminex Corporation. This critical addition provided DiaSorin with highly advanced multiplexing technology, allowing clinicians to simultaneously detect multiple pathogens or biomarkers in a single patient sample—a capability that is absolutely crucial for complex respiratory and gastrointestinal syndromic panels.

Operating multiple advanced manufacturing and R&D facilities across Europe and North America, DiaSorin maintains an unwavering commitment to continuous scientific innovation. Their strict strategic focus on specialty diagnostics allows the organization to maintain a dominant, highly trusted presence in specialty clinical laboratories worldwide.